Arch Biopartners Inc.
ARCH.V
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -67.77% | 459.12% | |||
| Gross Profit | 67.77% | -459.12% | |||
| SG&A Expenses | -74.20% | 201.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -71.98% | 720.44% | |||
| Operating Income | 71.98% | -720.44% | |||
| Income Before Tax | 66.50% | -470.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.50% | -470.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.50% | -470.95% | |||
| EBIT | 71.98% | -720.44% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 66.86% | -463.33% | |||
| Normalized Basic EPS | 66.98% | -457.89% | |||
| EPS Diluted | 66.86% | -463.33% | |||
| Normalized Diluted EPS | 66.98% | -457.89% | |||
| Average Basic Shares Outstanding | 1.26% | 0.92% | |||
| Average Diluted Shares Outstanding | 1.26% | 0.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||